Amneal Pharmaceuticals, Inc. (AMRX)
NASDAQ: AMRX · Real-Time Price · USD
13.81
-0.68 (-4.69%)
At close: Feb 27, 2026, 4:00 PM EST
13.55
-0.26 (-1.88%)
After-hours: Feb 27, 2026, 7:56 PM EST
Amneal Pharmaceuticals Stock Forecast
Stock Price Forecast
The 4 analysts with 12-month price forecasts for Amneal Pharmaceuticals stock have an average target of 13.25, with a low estimate of 11 and a high estimate of 15. The average target predicts a decrease of -4.06% from the current stock price of 13.81.
Analyst Consensus: Buy
* Price targets were last updated on Dec 9, 2025.
Analyst Ratings
The average analyst rating for Amneal Pharmaceuticals stock from 4 stock analysts is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Sep '25 | Oct '25 | Nov '25 | Dec '25 | Jan '26 | Feb '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 1 | 0 | 0 | 0 | 0 | 0 |
| Buy | 3 | 3 | 3 | 4 | 4 | 4 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 4 | 3 | 3 | 4 | 4 | 4 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Barclays | Barclays | Buy Initiates $15 | Buy | Initiates | $15 | +8.62% | Dec 9, 2025 |
| Piper Sandler | Piper Sandler | Buy Reiterates $11 → $13 | Buy | Reiterates | $11 → $13 | -5.87% | Oct 31, 2025 |
| JP Morgan | JP Morgan | Buy Maintains $12 → $14 | Buy | Maintains | $12 → $14 | +1.38% | Sep 16, 2025 |
| Barclays | Barclays | Buy Maintains $10 → $11 | Buy | Maintains | $10 → $11 | -20.35% | Mar 3, 2025 |
| JP Morgan | JP Morgan | Hold → Buy Upgrades $9 → $12 | Hold → Buy | Upgrades | $9 → $12 | -13.11% | Feb 24, 2025 |
Financial Forecast
Revenue This Year
3.27B
from 3.02B
Increased by 8.46%
Revenue Next Year
3.55B
from 3.27B
Increased by 8.28%
EPS This Year
0.96
from 0.22
Increased by 334.24%
EPS Next Year
1.18
from 0.96
Increased by 23.85%
Revenue Forecast
| Revenue | 2026 | 2027 |
|---|---|---|
| High | 3.4B | 3.7B |
| Avg | 3.3B | 3.5B |
| Low | 3.1B | 3.3B |
Revenue Growth
| Revenue Growth | 2026 | 2027 |
|---|---|---|
| High | 12.3% | 12.9% |
| Avg | 8.5% | 8.3% |
| Low | 3.4% | 2.1% |
EPS Forecast
| EPS | 2026 | 2027 |
|---|---|---|
| High | 1.08 | 1.29 |
| Avg | 0.96 | 1.18 |
| Low | 0.85 | 1.10 |
EPS Growth
| EPS Growth | 2026 | 2027 |
|---|---|---|
| High | 391.6% | 35.2% |
| Avg | 334.2% | 23.9% |
| Low | 284.4% | 14.9% |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.